-
Product Insights
AC Versailles – Saint-Germain-En-Laye National Inclusive Education Center (PNEI) – Ile-de-France
The AC Versailles – Saint-Germain-En-Laye National Inclusive Education Center (PNEI) – Ile-de-France involves the redevelopment of the National Inclusive Education Center (PNEI) on a 6,500m2 area in Saint-Germain-en-Laye Commune, Yvelines Department, Île-de-France Region, France. Equip yourself with the essential tools needed to make informed and profitable decisions with our AC Versailles – Saint-Germain-En-Laye National Inclusive Education Center (PNEI) – Ile-de-France report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0176 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0176 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0176 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0682 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0682 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0682 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Follicular Lymphoma Drug Details: AC-0676 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0699 in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AC-0699 in Metastatic Breast Cancer Drug Details: AC-0699 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-4024484 in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-4024484 in Malaria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-4024484 in Malaria Drug Details: GSK-4024484 is under development for the treatment...
-
Product Insights
NewBiological Dynamics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biological Dynamics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biological Dynamics Inc (Biological Dynamics) operates as a molecular diagnostics company. The company’s proprietary lab-on-a-chip (LOC) platform, Verita utilizes AC electrokinetics (ACE) technology for isolation of nanoparticles and macromolecules from biofluids includes whole blood, plasma and serum. It also develops lung assay to support treatment response in for patients with non-small cell lung cancer. Biological Dynamics utilizes its platform...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dazdotuftide in Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dazdotuftide in Glaucoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dazdotuftide in Glaucoma Drug Details: dazdotuftide (TRS-01) is under development for treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dazdotuftide in Ocular Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dazdotuftide in Ocular Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dazdotuftide in Ocular Inflammation Drug Details: dazdotuftide (TRS-01) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dazdotuftide in Anterior Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dazdotuftide in Anterior Uveitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dazdotuftide in Anterior Uveitis Drug Details: dazdotuftide (TRS-01) is under development...